Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis
Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L
PloS one · 107 citations
How it was studied
- Design
- Meta-analysis (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
Based on full-text disclosure statement.
Publication
- Published
- 2014-09-08 · PLoS One · vol. 9 · issue 9 · p. e107418
- Publisher
- Public Library of Science
- Cited
- 185 citations · more than 91% of similar papers · 2.7× the field average
- Impact
- Top 10% most cited in its field
- References
- 65 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Oral health in cancer treatment · Laser Applications in Dentistry and Medicine · Bone health and treatments
- Keywords
- Mucositis, Medicine, Placebo, Low level laser therapy, Meta-analysis, Confidence interval, Relative risk, Randomized controlled trial, Internal medicine, Hematopoietic stem cell transplantation, Incidence (geometry), Surgery, Transplantation, Chemotherapy, Laser therapy, Pathology
- MeSH
- humans, stomatitis, hematopoietic stem cell transplantation, low-level light therapy
5 authors
From CA, US
- Sapna OberoiHospital for Sick Children
- Gabriele Zamperlini–NettoHospital for Sick Children
- Joseph BeyeneHospital for Sick Children; SickKids Foundation; Institute for Clinical Evaluative Sciences; McMaster University
- Nathaniel Simon TreisterBrigham and Women's Hospital
- Lillian Sung · correspondingHospital for Sick Children; SickKids Foundation; Institute for Clinical Evaluative Sciences
Abstract
Background
Objective was to determine whether prophylactic low level laser therapy (LLLT) reduces the risk of severe mucositis as compared to placebo or no therapy.
Methods
MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched until February 2014 for randomized controlled trials (RCTs) comparing prophylactic LLLT with placebo or no therapy in patients with cancer or undergoing hematopoietic stem cell transplantation (HSCT). All analyses used random effects models.
Results
Eighteen RCTs (1144 patients) were included. Prophylactic LLLT reduced the overall risk of severe mucositis (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.20 to 0.67; P = 0.001). LLLT also reduced the following outcomes when compared to placebo/no therapy: severe mucositis at the time of anticipated maximal mucositis (RR 0.34, 95% CI 0.20 to 0.59), overall mean grade of mucositis (standardized mean difference -1.49, 95% CI -2.02 to -0.95), duration of severe mucositis (weighted mean difference -5.32, 95% CI -9.45 to -1.19) and incidence of severe pain (RR 0.26, 95% CI 0.18 to 0.37).
Conclusion
Prophylactic LLLT reduced severe mucositis and pain in patients with cancer and HSCT recipients. Future research should identify the optimal characteristics of LLLT and determine feasibility in the clinical setting.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.